COX-2s Patient Response Variability Could Lead To Diagnostic Tests
Executive Summary
Variability in patient responses to COX-2 inhibitors could lead to the development of diagnostic tests to select who should continue use of the drugs, a study in the January issue of Gastroenterology suggests
You may also be interested in...
Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says
The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments
Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says
The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13